2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Cell Expansion, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Women’s Health, Adverse Events, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Bleeding and Clotting, Bone Marrow Failure Syndromes, Hemoglobinopathies, Sickle Cell Disease, Immunology, GVHD, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric
PAPER

4259 Impact of survivorship clinic on long-term allogeneic hematopoietic cell transplantation outcomes

Jessica El-Asmar, MD, MPH, Xuefei Jia2, Christina Ferraro, BSN, RN3, Kayla Giannetti4, Claudio Brunstein, MD, PhD5, Matt Kalaycio, MD6, Marcelo Pasquini, MD7, Ronald Sobecks, Professor of Medicine8, Andrew Trunk, MD9, Rabi Hanna, MD10, Seth Rotz, MD11, Betty Hamilton, MD12
1 Cleveland Clinic Foundation, Cleveland, Ohio, United States
2 Cleveland Clinic Foundation, Cleveland, Ohio, United States
3 Cleveland Clinic Foundation, Cleveland, Ohio, United States
4 Cleveland Clinic Foundation, Cleveland, Ohio, United States
5 Cleveland Clinic Foundation, Cleveland, Ohio, United States
6 Cleveland Clinic Foundation, Cleveland, Ohio, United States
7 Cleveland Clinic Foundation, Cleveland, Ohio, United States
8 Cleveland Clinic Foundation, Cleveland, Ohio, United States
9 Cleveland Clinic Foundation, Cleveland, Ohio, United States
10 Cleveland Clinic Foundation, Cleveland, Ohio, United States
11 Cleveland Clinic Foundation, Cleveland, Ohio, United States
12 Cleveland Clinic Foundation, Cleveland, Ohio, United States

Background: Long-term survivors of allogeneic hematopoietic cell transplantation (allo-HCT) are at higher risk of late effects, leading to increased morbidity and mortality compared to the general population. Survivorship care has been recommended to address screening and preventative practices, but there is limited data on the impact of dedicated survivorship clinics on post-HCT outcomes. We performed an analysis of the impact of a survivorship clinic on long-term outcomes in allo-HCT recipients.

 

Methods: This is a single-institution retrospective study of adult recipients of allo-HCT between 1/2013-12/2020 who survived at least 1 year post-HCT without relapse. Our survivorship clinic was established 10/2016 and we identified a survivorship cohort (Survivor) which included patients transplanted between 7/2016-12/2020 and had at least 1 survivorship visit post-HCT (day 100 and/or 1 year). A propensity score - matched (based on age, sex, disease risk index, and donor source) historic cohort (Hist) transplanted 01/2013-06/2016 was analyzed and compared with the Survivor cohort; after subsequent exclusion of ineligible patients, residual baseline imbalances between cohorts were accounted for using multivariable adjustment. Outcomes included non-relapse mortality (NRM), overall survival (OS), quality of life (QOL), and late effects (second malignancies and cardiovascular events including heart failure, coronary artery disease, atrial fibrillation/flutter, or stroke).

 

Results: We identified a total of 343 patients meeting inclusion criteria; 216 in Survivor cohort, and 127 in Hist cohort. Median age at time of HCT was 60 years in Survivor group and 57 years in Hist group (p=0.016). More patients in the Survivor group had high HCT-comorbidity index (3+) (56%) versus the Hist group (39%), p=0.005; and underwent reduced-intensity HCT (63% versus 49%), p=0.018. Within the Survivor group, 94% had a day 100 survivorship visit, and 82% had a 1-year survivorship visit. 5-year OS and NRM were better in the Survivor cohort compared to Hist group (70% vs 65%, p=0.28); and (15% vs 20%, p=0.23), respectively, however both did not reach statistical significance. In patients with available QOL data ≥2 years post-HCT, fewer Survivors (n=206) reported poor PROMIS physical health compared to Hist (n=74) (18% vs 32% with T-score <40, p=0.026). Lower depression PHQ-9 (9% vs 12% score ≥10, p=0.710), distress (18% vs 21% scores ≥4, p=0.606), and less reporting poor PROMIS mental health (10% vs 20% T-score <40, p=0.059) was seen in Survivors compared to Hist. Second malignancies were similar between Survivor and Hist group (13% vs 16%, p=0.495). Eligible Survivors had significantly better mammography screening (73% vs 35%, p<0.001); and while there was more colonoscopy screening in Survivors, this was not significant (19% vs 10%, p=0.094), and notably there were low rates in both groups. In contrast, we found a significantly lower rate of cardiovascular events in Survivor compared to Hist groups (8% vs 26%, p<0.001).  

Multivariable analyses with Survivorship clinic as the main variable of interest demonstrated the Survivorship group was associated with significantly lower NRM (HR 0.49, 95%CI (0.21, 1.14), p=0.028); whereas moderate-severe chronic GVHD was associated with higher NRM (HR 2.2, p=0.007). High HCT-CI (HR 1.97, p=0.042) and moderate-severe chronic GVHD (HR 1.72, p=0.015) were associated with worse OS, whereas the favorable association of OS with Survivorship clinic did not reach statistical significance (HR 0.49, 95%CI (0.21-1.14), p=0.098).

 

Conclusion: This analysis demonstrates several significant impacts on outcomes of a survivorship clinic, including improved patient-reported physical health, cardiovascular events, and non-relapse mortality. Given limitations of this single-institution analysis, additional studies in multi-center cohorts are needed.

Jessica El-Asmar, MD, MPH: No relevant conflicts of interest to declare.